The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...

The National Multiple Sclerosis Society, the leading global organization supporting and empowering people living with ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

is the most common type of multiple sclerosis (MS), making up about 85% of diagnoses. RRMS involves periods known as relapses, during which symptoms worsen, followed by periods of symptom ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Multiple sclerosis (MS) is an autoimmune neurological ... They are very different conditions, but they sometimes share similar symptoms. Both conditions require a variety of medical tests for ...